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Since its introduction, transcatheter aortic valve replacement
(TAVR) has emerged as a new therapeutic option for
patients with inoperable, severe aortic stenosis and as an
alternative treatment modality to surgical aortic valve
replacement (SAVR) in selected, high-risk patients (1,2).
Because it is less invasive, this novel treatment is highly
attractive to both physicians and patients. Not surprisingly,
the use of TAVR has been increasing exponentially in
Europe and North America. The available data on TAVR
versus SAVR for patients at a higher surgical risk show
similar outcomes for both groups (3). Therefore, to identify
individuals who beneﬁt more from 1 therapy or the other,
a discriminating look at this heterogeneous group of high-
risk, but still operable, patients is mandatory.See pages 1090 and 1100In this issue of the Journal, 2 substudies from the high-
risk for surgery cohort (i.e., cohort A) of the PARTNER
(Placement of Aortic Transcatheter Valve) trial focus on
this important matter. The objective of the ﬁrst study
by Lindman et al. (4) was to determine clinical outcomes
in patients with aortic stenosis after TAVR compared
with SAVR by using a post-hoc analysis stratiﬁed according
to diabetes status. In contrast to nondiabetic patients, among
those with diabetes (42% of the total cohort), all-cause
mortality at 1 year was signiﬁcantly lower in the TAVR
group compared with the SAVR group (18.0% vs. 27.4%).
There was a signiﬁcant interaction between diabetes and
treatment group for 1-year all-cause mortality, and results
were consistent among patients treated by using the trans-
femoral (TF) or transapical (TA) approach. Renal failure
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to the contents of this paper to disclose.SAVR group (6.1% vs. 0%), but 1-year stroke rates were
similar between groups (3.5% TAVR vs. 3.5% SAVR).
The authors (4) have to be congratulated for this ﬁrst report
on an improved outcome by transcatheter versus surgical
therapy of severe aortic stenosis in diabetic high-risk patients.
For SAVR, increased morbidity and mortality in diabetic
patients compared with nondiabetic subjects have already
been shown (5). Cardiac surgery and cardiopulmonary bypass
can initiate a systemic inﬂammatory response syndrome
(SIRS) that is associated with adverse outcome (6). Tissue
ischemia–reperfusion injury seems to be the major cause for
the release of various inﬂammatory mediators, and diabetic
patients are more sensitive to the following oxidative stress
and inﬂammation (7). Interestingly, SIRS has also been
described in TAVR-treated patients and was associated with
an unfavorable impact on survival (8). The number of
ventricular pacing runs turned out to be an independent
predictor for SIRS, supporting the hypothesis that tissue
ischemia plays a key role. Although markers of inﬂammation
were not systematically measured in the current study, white
blood cell counts 24 h after the procedure tended to be lower
in diabetic patients undergoing TAVR compared with those
undergoing SAVR. This ﬁnding provides some support for
the notion that SAVR may induce a greater amount of
inﬂammation than TAVR in diabetic patients. The inﬂam-
mation does not necessarily result in a higher cardiovascular
mortality, but it may lead to increased noncardiac mortality,
as found in the current study.
Based on these ﬁndings, is TAVR the preferable treatment
in diabetic patients with high surgical risk? Although the
work of Lindman et al. (4) is an important contribution to our
understanding of patient selection for TAVR or SAVR, the
deﬁnitive answer is still pending. The authors do not provide
us with reliable information on diabetic medication (insulin
and/or oral medications) or on the severity or duration of
diabetes. In addition, data on glucose control in the study
population are lacking and could be confounding. Moreover,
the difference in mortality was no longer present after 2 years.
This ﬁnding might be caused by patients’ comorbidities, but
it raises a question about the long-term effect of TAVR: does
aortic regurgitation, which is more signiﬁcant after TAVR,
diminish the beneﬁcial treatment effect over time? Finally,
this was not a randomized trial, nor was it a pre-speciﬁed
subgroup analysis; therefore, as the authors correctly state,
these results should be considered hypothesis-generating and
must be conﬁrmed in future studies.
In the second study in this issue of the Journal, Généreux
et al. (9) sought to identify the incidence, predictors, and
prognostic impact of bleeding complications (BC) after SAVR
compared withTAVR from the PARTNER I trial.Within 30
days of the procedure, SAVR compared with TF- and TA-
TAVR was associated with signiﬁcantly more major BC and
an almost 3 times higher rate of transfusion. Independent
predictors of major BC were major vascular complications and
the use of intra-procedural hemodynamic support among TF-
TAVRpatients, procedural complications requiring conversion
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1111to open surgery among TA-TAVR patients, and low baseline
hemoglobin levels among SAVR patients. In accordance with
previous studies, major BC were identiﬁed as a strong inde-
pendent predictor of 1-year mortality among the full cohort
(12). The surprising result of the current study, however, was
that BC had a signiﬁcant impact on prognosis after SAVR but
not after TAVR.
The authors are to be complimented on this important
analysis (9), which is currently the largest on this topic.
Although other studies have already reported rates of
bleeding after TAVR (10) or after TAVR compared with
SAVR (11), the strength of the study by Généreux et al. (9)
is the relative homogeneity of its patient population, the
independent adjudication of events, and the direct com-
parison with a surgical cohort of similar risk. However, the
study has several limitations. The PARTNER trial was
performed by using ﬁrst-generation devices (22- and 24-F
introducer sheath diameter for TF and 29-F for TA), with
operators and sites at the beginning of their learning curve.
Considering the ongoing evolution toward lower-proﬁle
TAVR devices, even greater differences between TAVR
and SAVR in rates of BC and transfusion are likely to be
seen in the future.
The reason why major BC inﬂuence the prognosis
after SAVR but not after TAVR is not completely under-
stood (9). Speciﬁc causes of bleeding and reasons for
transfusions were not systematically documented. However,
the BC after surgery seemed to be more severe: among
patients receiving transfusions, the proportion of patients
receiving 4 transfusions was almost twice as high in the
SAVR group compared with the TF-TAVR group. There
is a close relationship between the severity of the initial
bleeding event and the impact on survival. Accordingly,
blood transfusion rate has been shown to be a predictor
of inﬂammation and adverse outcome in cardiac surgery
patients (13).
Although low baseline hemoglobin level was the only
independent predictor for major BC after SAVR, the
difference in hemoglobin between patients with and with-
out major BC was only 0.6 g/dl (9). This difference is too
small to be helpful in identifying patients at high risk for
bleeding after surgery but seems to reﬂect a higher comor-
bidity of the patients who experience BC.
Although both studies (4,9) are important contributors
to our understanding of suitable patient selection for TAVR
or SAVR, further studies are needed before we can reliablydetermine the population for whom aortic valve replacement
is done best with closed chest.
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